Abstract
Background: Mastitis is a common inflammatory condition of the breast, often requiring effective antibiotic treatment. This study evaluates the efficacy of tedizolid phosphate in treating mastitis among patients in an outpatient setting. Methods: A total of 100 patients diagnosed with mastitis at the OPD of Prime Hospital, Maijdee, Noakhali, were enrolled in this study between July 1, 2023, and June 30, 2024. Patients received tedizolid phosphate, and outcomes were assessed through clinical examination and follow-up. The study focused on symptom resolution, duration of antibiotic course, and adjunctive treatments. Result: The majority of patients (45.0%) were aged 21-30 years. The most common symptoms were breast pain (60.0%), breast lump (40.0%), and nipple discharge (25.0%). All participants underwent imaging, with 45.0% showing mastitis in the right breast and 30.0% in the left. Tedizolid phosphate was prescribed to 100% of patients, with completing a 6-day course. Symptom improvement was observed in 85.0% of cases, with partial improvement in 15.0%. No cases of non-improvement or worsening were recorded. Conclusion: Tedizolid phosphate demonstrated high efficacy in treating mastitis, with a significant proportion of patients achieving full symptom resolution. The findings support its use as a reliable treatment option, though further studies with longer follow-up and microbiological analyses are recommended to confirm these results.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call